Biopharmaceutical company developing novel small molecule medicines for genetic diseases caused by nonsense mutations

http://markets.businessinsider.com/news/stocks/Eloxx-Pharmaceuticals-Announces-Expansion-of-Intellectual-Property-Estate-for-ELX-02-with-Newly-Granted-Patent-in-Europe-1004482616

Eloxx Pharmaceuticals Announces Expansion of Intellectual Property Estate for ELX-02 with Newly Granted Patent in Europe

Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Continue reading Biopharmaceutical company developing novel small molecule medicines for genetic diseases caused by nonsense mutations

New Inhaled Antibiotic To Treat Respiratory Infections

https://www.europeanpharmaceuticalreview.com/news/67983/polyphor-antibiotic-murepavadin/

Polyphor launches the development of an inhaled antibiotic murepavadin

Polyphor Ltd has announced the development of an inhaled dosage form of its break­through antibiotic Murepavadin. Continue reading New Inhaled Antibiotic To Treat Respiratory Infections

Microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs

ahttps://www.eurekalert.org/pub_releases/2017-10/iuui-imu100517.php

IUPUI microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs

Individuals with cystic fibrosis, or CF, have a high risk of chronic pneumonia because the thick, sticky mucus that builds up in Continue reading Microbiologists uncover clues to clustering of lethal bacteria in CF patients’ lungs

DEADLINE EXTENDED for the Spring 2018 Lauren Melissa Kelly Scholarship!

We are extending the deadline until November 15, 2017!

The United States Adult Cystic Fibrosis Association (“USACFA”) offers the Lauren Melissa Kelly Scholarship award each semester, in honor of Lauren Melissa Kelly. The scholarships of up to $2500 are awarded to adults with cystic fibrosis who are pursuing career certifications, associates, and bachelor and graduate degrees.

Please find scholarship criteria and requirements on our website:

http://www.cfroundtable.com/announcements/united-states-adult-cystic-fibrosis-association-scholarship/

Nancy Wech, Lauren’s mother, established this scholarship in Lauren’s name and memory. In Nancy’s own words:

Lauren Melissa Kelly was an extraordinary woman. Laughing, gregarious, spontaneous, fun, talkative, driven, thoughtful, smart, kind and loving — all descriptive terms for Lauren, who lost her battle with CF late in her senior year at the University of Georgia. In 1992, Lauren was chosen as one of ten Senior Leaders at University of Georgia. She had distinguished herself as a member of the Golden Key Honor Society, Mortar Board, Phi Upsilon Omicron, Gamma Beta Phi, the Tate Society and Delta Gamma sorority.

Lauren felt the most significant opportunities of her college career included participation in the reconstruction and formation of organizations, which will serve the university in the future. She acted as one of the re-founding members of the Phi Kappa Literary Society and was significant in the metamorphosis of the Z Club into the William Tate Society. Her other activities included Greeks Advocating Mature Management of Alcohol (GAMMA) in which she served as Secretary and Special Events Chair. She was also a member of the Women’s Glee Club for more than two years.

In recognition of her academic performance, Lauren’s degree of Bachelor of Science in Family and Consumer Sciences was awarded posthumously. At the time of her death, Lauren was engaged to be married and living off campus in an apartment. She lived life to the fullest!

Walt Disney said, “Don’t cry because it’s over, smile because it happened. It’s not the days in life you remember, it’s the moments.” As Lauren’s mother stated, “I smile because she happened to me. Now, I want you to smile because she has happened to you.”

If you have any questions or concerns, reach out to us at scholarships@usacfa.org

 

New Pre-Clinical Data for Iclaprim

Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017™

https://globenewswire.com/news-release/2017/10/06/1142163/0/en/Motif-Bio-Presents-New-Pre-Clinical-Data-for-Iclaprim-at-IDWeek-2017.html

1. Pre-Clinical Data Support the Potential Use of Iclaprim in the Treatment of Staphylococcus aureus Pneumonia in Cystic Continue reading New Pre-Clinical Data for Iclaprim

New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’

http://markets.businessinsider.com/news/stocks/New-Nitric-Oxide-Treatment-Eradicates-Emerging-Superbugs-1002996746

Novoclem Therapeutics, a biotech company focused on advancing nitric oxide therapies for the treatment of respiratory diseases, today announced that data from an in vitro study with Continue reading New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’

Antifungal Drug Candidate Receives a Second “Qualified Infectious Disease Product” Designation

Pulmatrix Antifungal Drug Candidate Receives a Second “Qualified Infectious Disease Product” (QIDP) Designation from the FDA

http://markets.businessinsider.com/news/stocks/Pulmatrix-Antifungal-Drug-Candidate-Receives-a-Second-Qualified-Infectious-Disease-Product-QIDP-Designation-from-the-FDA-1002944255 Continue reading Antifungal Drug Candidate Receives a Second “Qualified Infectious Disease Product” Designation

Phase III study starts AVAIL study

Savara Announces Start of Pivotal Phase III AVAIL Study of AeroVanc

http://markets.businessinsider.com/news/stocks/Savara-Announces-Start-of-Pivotal-Phase-III-AVAIL-Study-of-AeroVanc-1002569033

Savara, Inc.(NASDAQ: SVRA), a clinical-stage specialty pharmaceutical company focused on the development Continue reading Phase III study starts AVAIL study